CBD for Treatment-Resistant Epilepsy: From Ancient Use to Modern Clinical Trials
Phase 3 trials of pharmaceutical CBD (Epidiolex) demonstrated efficacy and safety for Dravet and Lennox-Gastaut syndromes, while artisanal cannabis products remain unstandardized and unvalidated.
Quick Facts
What This Study Found
This review traced the evolution of cannabis-based epilepsy treatment from millennia of traditional use to modern randomized controlled trials.
The strongest evidence centered on Epidiolex (purified CBD at 100 mg/mL). Open-label studies showed efficacy with an adequate safety profile in children and young adults with a spectrum of treatment-resistant epilepsies. Phase 3 RCTs then confirmed efficacy and safety specifically for Dravet syndrome and Lennox-Gastaut syndrome at doses of 10 and 20 mg/kg/day.
The review highlighted a critical distinction between pharmaceutical-grade CBD and artisanal preparations available from dispensaries. While Epidiolex has undergone rigorous clinical evaluation, the dispensary products vary widely in composition and have no validated safety or efficacy data.
The authors noted the importance of the placebo effect in cannabis epilepsy research, given intense media attention and strong parental beliefs in natural products. Drug interactions, particularly with clobazam, were identified as an important safety consideration.
Key Numbers
30% of epilepsy patients are treatment-resistant. Epidiolex studied at 10 and 20 mg/kg/day. Phase 3 RCTs completed for Dravet syndrome and Lennox-Gastaut syndrome. 25 states plus DC had medical marijuana programs.
How They Did This
Review of case reports, small series, surveys, open-label studies, and Phase 3 RCTs of cannabinoids for treatment-resistant epilepsy, with focus on CBD (Epidiolex) for Dravet and Lennox-Gastaut syndromes.
Why This Research Matters
Treatment-resistant epilepsy affects 30% of epilepsy patients and carries severe morbidity and mortality. Epidiolex represents the first plant-derived cannabinoid to undergo rigorous clinical trial evaluation, setting a precedent for the field.
The Bigger Picture
The Epidiolex story represents a model for how cannabinoid medicine should develop: from traditional use and case reports through controlled trials to regulatory approval. It also highlights the tension between pharmaceutical development and the dispensary-based access that millions of patients use without equivalent evidence.
What This Study Doesn't Tell Us
The review captures a moment in time before FDA approval of Epidiolex (which came in 2018). Long-term safety data were still limited. The focus on Dravet and LGS may not apply to other epilepsy types. Drug interactions require ongoing study.
Questions This Raises
- ?Will CBD show efficacy for other epilepsy types beyond Dravet and LGS?
- ?Can artisanal CBD products be standardized to match pharmaceutical quality?
- ?What is the optimal long-term dosing strategy?
Trust & Context
- Key Stat:
- Phase 3 RCTs confirmed CBD (Epidiolex) efficacy for Dravet and Lennox-Gastaut syndromes
- Evidence Grade:
- Review incorporating Phase 3 RCT data, the highest tier of clinical evidence. Strong because the RCTs were large, placebo-controlled, and confirmatory.
- Study Age:
- Published in 2017, before FDA approval of Epidiolex in 2018.
- Original Title:
- Cannabinoids in treatment-resistant epilepsy: A review.
- Published In:
- Epilepsy & behavior : E&B, 70(Pt B), 341-348 (2017)
- Authors:
- O'Connell, Brooke K, Gloss, David(2), Devinsky, Orrin(9)
- Database ID:
- RTHC-01470
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does CBD help with epilepsy?
Pharmaceutical-grade CBD (Epidiolex) has demonstrated efficacy in Phase 3 RCTs for two severe childhood epilepsy syndromes: Dravet syndrome and Lennox-Gastaut syndrome. This led to FDA approval in 2018.
Is CBD from a dispensary the same as Epidiolex?
No. Epidiolex is a purified, standardized pharmaceutical product that has undergone rigorous clinical testing. Dispensary CBD products vary widely in composition and lack validated safety or efficacy data.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01470APA
O'Connell, Brooke K; Gloss, David; Devinsky, Orrin. (2017). Cannabinoids in treatment-resistant epilepsy: A review.. Epilepsy & behavior : E&B, 70(Pt B), 341-348. https://doi.org/10.1016/j.yebeh.2016.11.012
MLA
O'Connell, Brooke K, et al. "Cannabinoids in treatment-resistant epilepsy: A review.." Epilepsy & behavior : E&B, 2017. https://doi.org/10.1016/j.yebeh.2016.11.012
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in treatment-resistant epilepsy: A review." RTHC-01470. Retrieved from https://rethinkthc.com/research/o-connell-2017-cannabinoids-in-treatmentresistant-epilepsy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.